{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-014355","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.047729+00:00","generated_at":"2026-06-08T03:45:08.343097+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ENDRA Life Sciences Q3 net loss $3.1M; FDA De Novo review ongoing","bullets":["Net loss $3.1M ($0.40/share) vs $3.4M ($1.09/share) in Q3 2022; operating expense $3.1M.","Cash $3.3M at Sept 30; raised $1.2M via ATM equity facility during Q3.","TAEUS De Novo submission under substantive FDA review; clinical data showed 95% sensitivity.","Achieved 70 issued patents globally; targeting first European commercial orders near-term.","Presented at major liver disease conferences; expects MASLD treatment approvals in early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-014355","json":"https://secwatch.observer/filing/0001654954-23-014355.json","markdown":"https://secwatch.observer/filing/0001654954-23-014355.md","text":"https://secwatch.observer/filing/0001654954-23-014355.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423014355/0001654954-23-014355-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423014355/ndra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:45:08.343097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8e5a22b183e6e8979e08754330f8ae33d439c215","claim":"ENDRA Life Sciences Inc. reported the quarter ended September 30, 2023 results: net income Net loss in the third quarter of 2023 was $3.1 million, or $0.40 per share, EPS $0.40 per share.","evidence_excerpt":"ENDRA Life Sciences Inc . (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today reports financial results for the three and nine months ended September 30, 2023 and provides a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423014355/0001654954-23-014355-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss in the third quarter of 2023 was $3.1 million, or $0.40 per share"},{"label":"EPS","value":"$0.40 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}